Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of oxicam NSAIDs

被引：0
|
作者：
Suarez-Kurtz, Guilherme [1 ]
机构：
[1] Inst Nacl Canc, Div Pharmacol, BR-20231050 Rio De Janeiro, Brazil
来源：
PHARMACOGENETICS AND GENOMICS | 2014年 / 24卷 / 08期
关键词：
INDIVIDUALS; EXPOSURE;
D O I：
10.1097/FPC.0000000000000064
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：406 / 407
页数：2
相关论文
共 50 条
  • [1] Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of piroxicam
    Perini, Jamila A.
    Suarez-Kurtz, Guilherme
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (05) : 549 - 551
  • [2] Impact of CYP2C9 genotype on pharmacokinetics:: Are all NSAIDs the same?
    van Oijen, Martijn G. H.
    Laheij, Robert J. E.
    GASTROENTEROLOGY, 2007, 133 (06) : 2073 - 2074
  • [3] Comparison of the impact of the CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of the NSAIDS celecoxib, diclofenac, and ibuprofen.
    Kirchheiner, J
    Meineke, I
    Roots, I
    Brockmöller, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P75 - P75
  • [4] Impact of CYP2C9 genotype on pharmacokinetics:: Are all NSAIDs the same? -: Reply
    Pilotto, Alberto
    Franceschi, Marilisa
    Scarcelli, Carlo
    Niro, Valeria
    Seripa, Davide
    Colaizzo, Donatella
    Grandone, Elvira
    Andrjulli, Angelo
    Dallapiccola, Bruno
    Di Mario, Francesco
    Leandro, Gioacchino
    GASTROENTEROLOGY, 2007, 133 (06) : 2074 - 2075
  • [5] Influences of CYP2C9 genotype on pharmacokinetics and pharmacodynamics of benzbromarone.
    Uchida, S
    Shimada, K
    Misaka, S
    Yan, D
    Li, X
    Nishio, S
    Imai, H
    Ohashi, K
    Yamada, S
    Watanabe, H
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P13 - P13
  • [6] Pharmacokinetics and pharmacodynamics of meloxicam in relation to CYP2C9 genotype.
    Kim, Mi-Jung
    Jang, Choon-Gon
    Lee, Seok-Yong
    PHARMACOTHERAPY, 2012, 32 (10): : E234 - E234
  • [7] The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem
    Ji-Yeong Byeon
    Young-Hoon Kim
    Se-Hyung Kim
    Choong-Min Lee
    Eui-Hyun Jung
    Won-Ki Chae
    Choon-Gon Jang
    Seok-Yong Lee
    Yun Jeong Lee
    Archives of Pharmacal Research, 2018, 41 : 931 - 936
  • [8] The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem
    Byeon, Ji-Yeong
    Kim, Young-Hoon
    Kim, Se-Hyung
    Lee, Choong-Min
    Jung, Eui-Hyun
    Chae, Won-Ki
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    ARCHIVES OF PHARMACAL RESEARCH, 2018, 41 (09) : 931 - 936
  • [9] Influences of CYP2C9 genotype and fluvastatin on pharmacokinetics and pharmacodynamics of nateglinide.
    Uchida, S
    Nishio, S
    Li, XD
    Ito, T
    Morita, H
    Nakamura, H
    Yamada, H
    Watanabe, H
    Ohashi, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P74 - P74
  • [10] CYP2C9☆3 ALLELE MARKEDLY AFFECTS THE PHARMACOKINETICS AND PHARMACODYNAMICS OF MELOXICAM
    Park, J., I
    Choi, C., I
    Bae, J. W.
    Jang, C. G.
    Lee, S. Y.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 64 - 64
12345